EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Seelos Therapeutics, Inc. (SEEL) had EBIT Margin of -1838.36% for the most recently reported fiscal year, ending 2023-12-31.
Income Statement Financials | |
$2.20M |
|
$-37.88M |
|
-- |
|
$2.20M |
|
$42.70M |
|
$-40.50M |
|
$2.62M |
|
$-37.88M |
|
$-37.88M |
|
$-37.88M |
|
$-37.88M |
|
$-37.88M |
|
$-37.88M |
|
$-40.50M |
|
$-40.50M |
|
4.90M |
|
4.90M |
|
$-7.73 |
|
$-7.73 |
|
Balance Sheet Financials | |
$5.40M |
|
-- |
|
$0.01M |
|
$5.42M |
|
$38.93M |
|
-- |
|
-- |
|
$38.93M |
|
$-33.51M |
|
$-33.51M |
|
$-33.51M |
|
9.79M |
|
Cash Flow Statement Financials | |
$-23.91M |
|
-- |
|
$11.38M |
|
$15.53M |
|
$3.00M |
|
$-12.54M |
|
$3.99M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
0.14 |
|
-- |
|
-- |
|
-- |
|
-0.42 |
|
100.00% |
|
-1838.36% |
|
EBIT Margin |
-1838.36% |
-1838.36% |
|
-1719.56% |
|
-1719.56% |
|
$-23.91M |
|
-- |
|
-- |
|
-- |
|
0.41 |
|
-- |
|
-- |
|
-- |
|
113.05% |
|
113.05% |
|
-699.19% |
|
113.05% |
|
$-3.42 |
|
$-4.88 |
|
$-4.88 |